Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Verrica Pharmaceuticals (NASDAQ: VRCA ) stock is sinking over 50% in morning trading The FDA declined to approve its treatment for “a viral skin disease” According to Verrica, the agency declined to...
Verrica Pharma (NASDAQ:VRCA) continues to trade lower in the pre-market Wednesday after RBC Capital Markets downgraded the dermatology-focused company to Sector Perform from Outperform, citing the FDA rejection of its lead drug VP-102 for molluscum contagiosum. Issuing the so-called Complete ...
Verrica Pharmaceuticals' (NASDAQ:VRCA) stock fell ~59% premarket on May 25 after the U.S. Food and Drug Administration (FDA) declined to approve the company's medicine VP-102 to treat a viral skin disease called molluscum contagiosum (MC). MC is caused by a poxvirus that leads to small r...
Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised Verrica that the review of NDA was completed and label was ready to be communic...
Gainers: Wendy's Company (The) (WEN) +13%. WalkMe (WKME) +8%. Trevi Therapeutics (TRVI) +7%. Braze (BRZE) +6%. Photronics (PLAB) +6%. Losers: Verrica Pharmaceuticals (VRCA) -32%. InterDigital (IDCC) -8%. Chinook Therapeutics (KDNY) -7%. Grindrod Shipping Holdings (...
FDA re-inspected CMO in February 2022 and issued new Form 483. CMO has failed each of three inspections in four years. Corrective actions will take significant time. For further details see: Verrica Pharmaceuticals Should Receive Second CRL Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...
Verrica Pharmaceuticals press release (NASDAQ:VRCA): Q1 Non-GAAP EPS of -$0.25 beats by $0.20. Revenue of $0.4M (-96.7% Y/Y) beats by $0.07M. For further details see: Verrica Pharmaceuticals Non-GAAP EPS of -$0.25 beats by $0.20, revenue of $0.4M beats by $0.07M
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma WEST CHESTER, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatolog...
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...